15. February 2013
Climate change, PR measurement and the impact of "new" technologies on healthcare communications
What is the impact of climate change – cited as “the biggest global health threat of the 21st century” – on the health industry? Where is PR measurement heading to? In what way do "new" technologies change our attention spans and the actual physical makeup of our brains? Why has digital become so important for managing health and healthcare communications?
Read more about these topics and enjoy the new PRimeCut, issue Winter 2013!
13. December 2011
Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
London, December 12, 2011
– Chandler Chicco Companies (CCC), part of inVentiv Health, Inc., today announced that leading German healthcare communication firms, Haas & Health Partner Public Relations (Haas & Health Partner) and SanCom Creative Communication Solutions (SanCom CCS) have been acquired by CCC, creating an unrivalled healthcare communication capability in Germany.
The two Eltville, Germany-based companies, previously affiliated with CCC, will join inVentiv Health effective immediately. This will add a further 33 staff (23 of Haas & Health Partner and 10 of SanCom CCS) to CCC’s thriving European operations and provide the company’s clients with access to a pure-play healthcare communications network of more than 380 experts worldwide. In addition, the firms will be linked to the inVentiv Health Communications/Europe “super-agency” structure - a multi-disciplinary, pan-European operation which brings together inVentiv’s advertising, public relations, public policy, market access, medical education, marketing, branding and digital services.
In 2008, CCC strengthened its relationship with Haas & Health Partner and SanCom CCS by acquiring a 19.9% interest. Under the terms of the new agreement, the companies now become wholly-owned subsidiaries.
Over the last decade, Haas & Health Partner and SanCom CCS have delivered superior strategic thinking, creativity and integrated healthcare communication solutions with a focus on the German market. The companies’ approach is a natural fit with the Chandler Chicco Companies portfolio, known for its unmatched perspective, multi-disciplinary approach and creative know-how.
“This is a significant step in our global growth plans,” said Bob Chandler, founder and principal of Chandler Chicco Companies. “After a decade of working closely with both firms, the terms of our new agreement enable us to bring unprecedented resources to the German marketplace for the benefit of our clients’ interests.”
Whilst aligning under the Chandler Chicco Companies umbrella, both Haas & Health Partner, currently celebrating its 10th anniversary, and sister company SanCom CCS will retain their brands. Dr. Irene Haas, Ulrich van Gemmern and their existing management teams will also continue to lead the firms, reporting directly to Fiona Hall, Managing Director of Chandler Chicco Companies Europe.
“From the very beginning, Haas & Health Partner and SanCom CCS set out to deliver truly global propositions, rooted in the nuances of the local landscape here in Germany,” said Dr. Irene Haas and Ulrich van Gemmern, founders of the two companies. “In an increasingly globalised marketplace, our clients’ needs are changing. Today’s consolidation with Chandler Chicco Companies allows us to broaden our horizons even further – adding truly global resources to a well established and trusted local team.” EDITOR’S NOTESAbout Haas & Health Partner Public Relations
Haas & Health Partner Public Relations is a leading pure-play healthcare communications agency in Germany. The company provides public relations and integrated marketing services to healthcare clients, including market access support, medical education, dialogue marketing and promotional support. Haas & Health Partner combines intelligent strategies with creative ideas and measurable results.
For more information, visit www.haas-health.de
.About SanCom Creative Communication Solutions
SanCom Creative Communication Solutions is a pure-play integrated healthcare communications service provider with a focus on public relations and integrated marketing. Founded in 2007, SanCom CCS merges scientific understanding with strategic thinking and a highly creative approach, achieving outstanding successful communications solutions for healthcare clients.
For more information, visit www.sancom-ccs.de
.About Chandler Chicco Companies
Chandler Chicco Companies (CCC) is a global health communications group that delivers unmatched perspective and creative know-how. Taking an integrated approach to communications, CCC offers best-in-class capabilities spanning public relations, digital and social media, medical and scientific education, marketing and branding, graphic design and multimedia, event production, and research and measurement. Companies under the Chandler Chicco umbrella include: Allidura Consumer, Brandtectonics, Biosector 2, Chamberlain Healthcare Public Relations, Chandler Chicco Agency, Chandler Chicco Productions, Determinus, Haas & Health Partner Public Relations, Ingenda Communications, Litmus Medical Marketing & Education, ‘nition Design, SanCom Creative Communication Solutions, SharedVoice PR, and VerStone Digital.
CCC is part of inVentiv Health, Inc., and has wholly-owned offices in New York, London, Los Angeles, Eltville, Paris, and Washington, D.C.; and a global affiliate healthcare network operating across nearly 40 markets.About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organisation sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team.
For more information, visit www.inventivhealth.com
.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfil our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced acquisitions, and any additional leverage we may incur in connection with the financing thereof, on the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; the impact of any default by any of our credit providers or swap counterparties; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability accurately forecast insurance claims within our self-insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses, including the acquisitions of i3 Global and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; and the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Readers of this press release are referred to documents which may be filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors. For media inquiries, please contact:
Chandler Chicco Companies
Telephone: +44 020 7632 1800
Dr. Irene Haas
Haas & Health Partner Public Relations
Telephone: +49 6123 7057 10
Ulrich van Gemmern
SanCom Creative Communication Solutions
Telephone: +49 6123 70558 11
21. December 2009
(Eltville, in October 2009 – hhp) Medicines based on plasma proteins are high-tech drugs and indispensable to the treatment of many serious diseases. They are used to treat antibody deficiencies, auto-immune disorders, severe bacterial infections, clotting disorders dur-ing to surgery and viral infections due to organ transplantations – to give only a few applications. The German company Biotest AG researches, develops and produces special therapeutic solutions that fulfill the strictest quality requirements and are marketed and distri-buted worldwide. In order to facilitate a better understanding of these complex preparations and their application areas among the professional medical community, Biotest has recruited the Eltville PR agency Haas & Health Partner.
“Working us deeply into the science of immunoglobulins and other plasma protein preparations as well as their application areas, is a fascinating task,” says Managing Partner Dr. Irene Haas. “We are especially pleased that we will have the opportunity to shape communication activities not only in Germany, but also on an international scale.” Biotest AG is a global leader in the field of hyperimmunoglobulins and the only company to offer IgM-enriched immunoglobulins. Biotest AG also researches monoclonal antibodies and offers the most modern factor preparations for the treatment of patients with hemophilia A and B. The company’s headquarters are located in Dreieich near Frankfurt am Main.
Haas & Health Partner is an owner-run agency for healthcare communications. We combine intelligent strategies with creative ideas. We are the experts in healthcare communications committed to our clients’ success with knowledge and passion.